AI Science Tracker

TxGNN: repurposing existing drugs for rare diseases

Harvard Medical School · 25 Sep 2024 · medicine

Discovery

TxGNN: repurposing existing drugs for rare diseases

The model covers about 8,000 drugs across 17,080 diseases and is nearly 50% better than competitors at identifying candidates and 35% more accurate on contraindications. It was tested on 1.2 million medical records and on three rare diseases excluded from training. Computational predictions only, with no laboratory or clinical confirmation.

Technology: TxGNN (graph neural network)

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: retrospective or benchmark
  • Tested: The model was checked against about 8,000 drugs and 17,080 diseases, validated on 1.2 million medical records, and asked to find drugs for three rare diseases excluded from training; it was compared with leading drug-repurposing models.
  • Still unknown: Identified therapies would require further evaluation for dosing and delivery, and there is no laboratory or clinical confirmation.
  • AI role: Proposed existing drugs for thousands of diseases, predicted contraindications and side effects, and gave a rationale for each prediction.

Evidence sources: https://hms.harvard.edu/news/researchers-harness-ai-repurpose-existing-drugs-treatment-rare-diseases

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 303 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.